PHGE — Biomx Inc

Biomx Inc (PHGE) is a biotechnology company listed on NYSE MKT. It is led by Jonathan Eitan Solomon MBA, based in 22 Einstein Street, Ness Ziona, Israel, 7414003, with about 52 employees. BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.

Latest reported PHGE revenue for 2026-06-30 was $332.0K. Net income was -$3.8M. PHGE currently screens at market cap $11.5M and trailing P/E 0.0.

Use this PHGE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PHGE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PHGE SEC filings page. Lician reads the product cache first so this HTML stays unique to Biomx Inc even when a live quote feed is slow.